Vanda Pharmaceuticals | VNDA - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 256.47M 228.7M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Eli Lilly USD 14.59B 1.48B 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Insmed USD 217.69M 106.25M 2025-12
J&J USD 16.6B 118M 2025-12
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
Merck USD 13.42B 431M 2025-09
Minerva Neurosciences -4.27M 26.79M 2024-12
Moderna USD 226M 583M 2025-12
Novartis USD 10.82B 694M 2025-09
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Takeda JPY 790.55B 262.97B 2025-12
Teva Pharmaceutical Industries USD 2.66B 351M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12
Veracyte USD 101.97M 10.69M 2025-12